



# Gut Microbiota and Heart, Lung and Neurogenerative Diseases

Adeel Urrehman\* and Shahab Abid

## Keywords:

---

**\*Corresponding author:** Adeel Urrehman, Department of Medicine Section Gastroenterology, Aga Khan University Hospital, Pakistan, Tel: + 923322318394; E-mail: [adeelurrehmansiddiqui@gmail.com](mailto:adeelurrehmansiddiqui@gmail.com); [aurehman2000@yahoo.co.uk](mailto:aurehman2000@yahoo.co.uk)

**Received** June 24, 2020; **Accepted** October 20, 2020; **Published** October 27, 2020

**Citation:** Urrehman A, Abid S (2020) Gut Microbiota and Heart, Lung and Neurogenerative Diseases. *J Gastrointest Dig Syst* 10: 631.

**Copyright:** © 2020 Urrehman A, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

disturbed microbiome that further promote airway inflammation via pattern recognition receptor interactions and pathogen-associated molecular patterns [21].

There is significant decline of probiotic species along with likely rise of pathogenic bacteria seems to be the key factor for vulnerability, chronization and advancement of pulmonary diseases that results from Lung microbiome transformation. Chronic obstructive airway disease COPD patients commonly had *Pseudomonas* species while in healthy

---

in our daily lives. We need more research trials to explore further therapeutic options about Covid-19 so that we will be more organised in future if similar pandemic hit us again. Other organism like fungi and phages that also constitute a major portion of ecosystem in human gut might have a role for treatment options in Covid-19?

#### References

1. 7: 688-693.
2. The intestinal metabolome: an intersection between microbiota and host. *Gastroenterology*. 146: 1470-1476.
3. majority. *Proc Natl Acad Sci USA* 95: 6578-6583.
4. *Microbiol* 31: 107-133.
5. shaping microbial diversity in the human intestine. *Cell* 124: 837-848.
6. (2015) Trends *Microbiol* 23: 328-329.
7. Morgan AE, Mooney KM, Wilkinson SJ, Pickles NA, Mc Auley MT (2016) Cholesterol metabolism: a review of how ageing disrupts the biological
8. 18:68.
- 9.
10. cholesterol excretion is an active metabolic process modulated by PCSK9 and
11. Kazemian N, Mahmoudi M, Halperin F, Wu JC, Pakpour S (2020) Gut microbiota and cardiovascular disease: opportunities and challenges. *Microbiome* 8:36.
12. and restenosis: an assessment of the evidence and need for future research.
13. Mitra S, Drautz-Moses DI, Alhede M, Maw MT, Liu Y, et al. (2015) In silico analyses of metagenomes from human atherosclerotic plaque samples. *Microbiome* 3 :38.
14. Tang WH, Kitai T, Hazen SL (2017) Gut microbiota in cardiovascular health and
15. microbiota with reduced trimethylamine-Noxide level in patients with large-